Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT6A | Q92794 | 1/20 | 0.35 |
| ▸ | KAT5 | Q92993 | 1/20 | 0.35 |
| ▸ | BTK | Q06187 | 3/20 | 0.34 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.32 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.32 |
| ▸ | KAT8 | Q9H7Z6 | 1/20 | 0.31 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3244351 | 0.86 | BTK (0.40) | KAT6AKAT5BTKMAPK8DDR1 | |
| SCHEMBL3244356 | 0.86 | BTK (0.40) | KAT6AKAT5BTKMAPK8DDR1 | |
| Hydrochloric Acid SCHEMBL4161185 | 0.83 | GPR17 (0.32) | — | |
| Hydrochloric Acid SCHEMBL4161189 | 0.83 | GPR17 (0.32) | — | |
| Butyric Acid SCHEMBL4173769 | 0.83 | KAT6A (0.38) | KAT6AKAT5BTKMAPK8DDR1 | |
| SCHEMBL4161880 | 0.77 | BRD4 (0.43) | DDR1MCL1 | |
| SCHEMBL4171744 | 0.76 | PKM (0.35) | — | |
| SCHEMBL4153781 | 0.69 | KDM4E (0.32) | — | |
| SCHEMBL4153570 | 0.69 | SCN9A (0.32) | — | |
| SCHEMBL4171968 | 0.69 | PKM (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8426437-B2 | Pyrroloquinoline derivatives and their use as protein kinases inhibitors | PIERRE FABRE MEDICAMENT (FR) | 2013-04-23 | — | — | US | disclosed |
| US-20090042876-A1 | Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors | PIERRE FABRE MEDICAMENT (FR) | 2009-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042876-A1 | Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors | MAP3K1, MAP3K2, MAP3K7 | KAT6A 2033/4885KAT5 2720/4885BTK 176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.